论文部分内容阅读
目的探讨重组人白细胞介素24(rhIL-24)对SKOV3卵巢癌细胞株、卵巢癌顺铂(DDP)耐药SKOV3/DDP细胞株的抑制效应,并观察rhIL-24对卵巢癌SKOV3和SKOV3/DDP细胞凋亡和细胞周期的影响。方法用rhIL-24、DDP及rhIL-24联合DDP作用于SKOV3、SKOV3/DDP细胞,以CCK-8法检测细胞增殖、用流式细胞仪检测细胞凋亡及周期的变化。结果 rhIL-24对体外培养的卵巢癌SKOV3和SKOV3/DDP细胞的生长有明显抑制作用,rhIL-24联合DDP对SKOV3/DDP细胞株抑制率为30.7%,与单用DDP组抑制率6.5%相比有显著性差异,流式细胞仪检测rhIL-24、DDP和rhIL-24联合DDP各组凋亡率分别为14.95%、12.99%和16.32%,与阴性对照组凋亡率1.32%比较具有显著性差异;细胞周期检测中,SKOV3细胞周期变化显示rhIL-24组G2、S期增多,联合用药组出现S期增多;SKOV3/DDP细胞中,rhIL-24组处理出现G2期增多,联合用药组出现G1期增多。结论 rhIL-24对卵巢癌细胞DDP敏感和耐药株都具有抑制作用,联合用药可增强DDP的效应;rhIL-24对卵巢癌细胞的抑制作用通过诱导细胞凋亡实现,rhIL-24处理细胞后周期变化出现G2期阻滞,联合用药组出现G1期阻滞。
Objective To investigate the inhibitory effect of recombinant human interleukin-24 (rhIL-24) on SKOV3 ovarian cancer cell lines and cisplatin-resistant ovarian cancer cell lines (SKOV3 / DDP) and observe the effects of rhIL-24 on SKOV3 and SKOV3 / DDP apoptosis and cell cycle. Methods The proliferation of SKOV3 and SKOV3 / DDP cells was induced by rhIL-24, DDP and rhIL-24 combined with DDP. The cell proliferation was detected by CCK-8 assay. The apoptosis and cell cycle were detected by flow cytometry. Results rhIL-24 significantly inhibited the growth of ovarian cancer SKOV3 and SKOV3 / DDP cells in vitro. The inhibitory rate of rhIL-24 and DDP on SKOV3 / DDP cells was 30.7% The apoptotic rates of rhIL-24, DDP and rhIL-24 combined with DDP by flow cytometry were 14.95%, 12.99% and 16.32%, respectively, which was significantly lower than that of the negative control group (1.32%) In the cell cycle assay, the cell cycle changes of SKOV3 cells showed that the G2 and S phases increased in the rhIL-24 group and the S phase increased in the combination group; in the SKOV3 / DDP cells, the G2 phase increased in the rhIL-24 group, There G1 phase increased. Conclusion rhIL-24 can inhibit the proliferation of ovarian cancer cells DDP-sensitive and resistant strains, combined with DDP can enhance the effect; rhIL-24 on ovarian cancer cells by inducing apoptosis, rhIL-24-treated cells Cyclic changes appear G2 block, combined with G1 block group.